Detection of human papillomavirus DNA and p53 codon 72 polymorphism in prostate carcinomas of patients from Argentina

BMC Urology

Volumn 5, Issue , 2005, Pages

  Leiros, Gustavo J ^a   Galliano, Silvia R ^a   Sember, Mario E ^b   Kahn, Tomas ^c,d   Schwarz, Elisabeth ^c   Eiguchi, Kumiko ^a  

^a UNIVERSIDAD DEL SALVADOR   (Argentina)

^b Hospital Israelita   (Argentina)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d DEUTSCHE BANK AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53; VIRUS DNA;

ADULT; AGED; ARGENTINA; ARTICLE; CODON; CONTROLLED STUDY; DNA DETERMINATION; GENETIC CODE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PROSTATE CARCINOMA; PROTEIN DEGRADATION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SOUTHERN BLOTTING; VIRUS DETECTION; WART VIRUS;

ADENOCARCINOMA; ARGENTINA; DNA PROBES, HPV; DNA, VIRAL; GENES, P53; HUMANS; MALE; MIDDLE AGED; PAPILLOMAVIRIDAE; POLYMORPHISM, GENETIC; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS;

EID: 29144509826     PISSN: 14712490     EISSN: 14712490     Source Type: Journal    
DOI: 10.1186/1471-2490-5-15     Document Type: Article

References (26)

1. Ruijter E, van de Kaa C, Miller G, Ruiter D, Debruyne F, Schalken J: Molecular genetics and epidemiology of prostate carcinoma. Endocr Rev 1999, 20:22-45.
2. zur Hausen H: Papillomaviruses causing cancer: Evasion from host cell control in early events in carcinogenesis. J Natl Cancer Inst 2000, 92:690-698.
3. Key T: Risk factors for prostate cancer. Cancer Surv 1995, 23:63-77.
4. Moyret-Lalle C, Marcais C, Jacquemier J, Moles JP, Daver A, Soret JY, Jeanteur P, Ozturk M, Theillet C: Ras, p53 and HPV status in benign and malignant prostate tumors. Int J Cancer 1995, 64:124-129.
5. Cuzick J: Human papillomavirus infection of the prostate. Cancer Surv 1995, 23:91-95.
6. Strickler HD, Burk R, Shah K, Viscidi R, Jakcson A, Pizza G, Bertoni F, Schiller JT, Manns A, Metcalf R, Qu W, Goedert JJ: A multifaceted study of human papillomavirus and prostate carcinoma. Cancer 1998, 82:1118-1125.
7. Thomas M, Pim D, Banks L: The role of the E6-p53 interaction in the molecular pathogenesis of HPV. Oncogene 1999, 18:7690-7700.
8. Münger K, Basile JR, Duensing S, Eichten A, Gonzalez SL, Grace M, Zacny VL: Biological activities and molecular targets of the human papillomavirus E7 oncoprotein. Oncogene 2001, 20:7888-7898.
9. Matlashewski GJ, Tuck S, Pim D, Lamb P, Schneider J, Crawford LV: Primary structure polymorphism at amino acid residue 72 of human p53. Mol Cell Biol 1987, 7:961-963.
10. Storey A, Thomas M, Kalita A, Harwwod C, Gardiol D, Mantovani F, Brever J, Leight IM, Matlashewski G, Banks L: Role of p53 polymorphism in the development of human papillomavirus-associated cancer. Nature 1998, 393:229-234.
11. Zehbe I, Voglino G, Wilander E, Delius H, Marongiu A, Edler L, Klimek F, Andersson S, Tomamasino M: P53 codon 72 polymorphism and various human papillomavirus 16 E6 genotypes are risk factors for cervical cancer development. Cancer Res 2001, 61:608-611.
12. Malcolm EK, Baber GB, Boyd JC, Stoler MH: Polymorphism at codon 72 of p53 is not associated with cervical cancer risk. Mod Pathol 2000, 13:373-378.
13. Henner WD, Evans AJ, Hough KM, Harris EL, Lowe BA, Beer TM: Association of codon 72 polymorphism of p53 with lower prostate cancer risk. Prostate 2001, 49:263-266.
14. Hoffmann M, Kahn T, Mahnke CG, Goeroegh T, Lippert BM, Werner JA: Prevalence of human papillomavirus in squamous cell carcinoma of the head and neck determined by polymerase chain reaction and southern blot hybridization: Proposal for optimized diagnostic requirements. Acta Otolaryngol (Stockh) 1998, 118:138-144.
15. Grussendorf-Conen E, Deutz FJ, de Villiers EM: Detection of human papillomavirus-6 in primary carcinoma of the urethra in men. Cancer 1987, 60:1832-1835.
16. Mevorach RA, Cos LR, di Sant Agnese PA, Stoler M: Human papillomavirus type 6 in grade I transitional cell carcinoma of the urethra. J Urol 1990, 143:126-128.
17. Scholefield JH, Hickson WG, Smith JH, Rogers K, Sharp F: Anal intraepithelial neoplasia: part of a multifocal disease process. Lancet 1992, 340:1271-1273.
18. Beckmann AM, Daling JR, Sherman KJ, Maden C, Miller BA, Coates RJ, Kiviat NB, Myerson D, Weiss NS, Hislop TG: Human papilomavirus infection and anal cancer. Int J Cancer 1989, 43:1042-1049.
19. Serth J, Panitz F, Paeslack U, Kuczyk MA, Jonas U: Increased levels of human papillomavirus type 16 DNA in a subset of prostate cancers. Cancer Res 1999, 59:823-825.
20. Noda T, Sasagawa T, Dong Y, Fuse H, Namiki M, Inoue M: Detection of human papillomavirus (HPV) DNA in archival specimens of benign prostatic hyperplasia and prostatic cancer using a highly sensitive nested PCR method. Urol Res 1998, 26:165-169.
21. Saad F, Gu K, Jean-Baptiste J, Gauthier J, Mesmasson AM: Absence of human papillomavirus sequences in early stage prostate cancer. Can J Urol 1999, 6:834-838.
22. Rosenthal A, Ryan A, Al-Jehani RM, Storey A, Harwood CA, Jacobs IJ: p53 codon 72 polymorphism and risk of cervical cancer in UK. Lancet 1998, 352:871-872.
23. Josefsson A, Magnusson PK, Ylitalo N, Magnusson P, Ylitalo N, Quarforth-Tubbin P, Ponten J, Adami H, Gyllensten U: p53 polymorphism and risk of cervical cancer. Nature 1998, 396:531-532.
24. Giannoudis A, Graham DA, Southern SA, Herrington CS: P53 codon 72 Arg/Pro polymorphism is not related to HPV type or lesion grade in low- and high- grade squamous intra-epithelial lesions and invasive squamous carcinoma of the cervix. Int J Cancer 1999, 83:66-69.
25. Zehbe I, Voglino G, Wilander E, Genta F, Tommasino M: Codon 72 polymorphism of p53 and its association with cervical cancer. Lancet 1999, 354:218-219.
26. Szarka K, Veress G, Juhasz A, Konya J, Sapy T, Soos G, Hernadi Z, Gergely L: Integration status of virus DNA and p53 codon 72 polymorphism in human papillomavirus type 16 positive cervical cancers. Anticancer Res 2000, 20:2161-2167.